Boston Scientific Q3 2024 Adj. EPS $0.63 Beats $0.59 Estimate, Sales $4.209B Beat $4.039B Estimate
Portfolio Pulse from Benzinga Newsdesk
Boston Scientific reported its Q3 2024 financial results, with adjusted EPS of $0.63 surpassing the estimated $0.59, and sales of $4.209 billion exceeding the expected $4.039 billion.
October 23, 2024 | 10:31 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Boston Scientific's Q3 2024 results exceeded expectations with an adjusted EPS of $0.63 and sales of $4.209 billion, both beating analyst estimates.
The company's better-than-expected earnings per share and sales figures are likely to positively impact its stock price in the short term as they indicate strong financial performance and operational efficiency.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100